All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.
The Federal Trade Commission sent warning letters in late 2024 to multiple online sellers of compounded tirzepatide and semaglutide. The letters target advertising claims that omit material information about prescription status, safety risks, and the unapproved nature of compounded peptides. Sellers who continue such practices face penalties up to $50,120 per violation.
The development: what the FTC letters actually say
The FTC letters cite three recurring problems. 1) Ads describe tirzepatide or semaglutide as "FDA-approved" when the compounded versions are not. 2) Ads fail to disclose that these products require a prescription. 3) Ads use before-and-after photos or weight-loss testimonials without adequate substantiation. The letters demand removal of deceptive claims within 15 days.
A 2024 FTC staff perspective on health claims (FTC 2024) notes that disease-treatment claims require competent and reliable scientific evidence. For compounded GLP-1s, that evidence does not exist at the level required for consumer advertising. The agency treats omission of prescription status as a deceptive act under Section 5 of the FTC Act.
Regulatory context: FTC authority over compounded peptide ads
The FTC has jurisdiction over advertising, not drug approval. That distinction matters. The FDA regulates whether a compounded drug can be sold. The FTC regulates what a seller can say about it. A seller can hold a valid FDA compounding registration and still violate FTC rules through ad copy.
Three enforcement triggers appear in the latest letters. First, any claim that compounded semaglutide is "just like Ozempic" or "generic Wegovy" is false because no generic version of those drugs exists. Second, pricing claims like "$48 per vial" that omit the cost of a required telehealth consult are misleading. Third, use of the word "safe" without qualification is an express claim that requires proof.
Compounded tirzepatide and semaglutide sit in a legal gray zone. The FDA allows compounding when a drug is in shortage. Semaglutide remains on the FDA shortage list as of early 2025. Tirzepatide was removed from shortage in late 2024, which triggered a wave of compounding restrictions. The FDA panel vote on six peptides could further narrow access to tirzepatide compounding.
Industry response: telehealth platforms and compounding pharmacies adjust
Several large telehealth platforms removed weight-loss claims from their compounded GLP-1 landing pages within days of the FTC letters. One platform replaced "lose up to 20% body weight" with "prescription medication for metabolic health." Another added a mandatory checkbox confirming the user understands the product is not FDA-approved.
Compounding pharmacies face a separate pressure. The FDA has found subpotent tirzepatide in some compounded formulations (FDA 2024). That finding, combined with FTC ad scrutiny, pushes pharmacies toward stricter disclaimers. Some now require a signed acknowledgment before shipping. Others stopped advertising compounded semaglutide entirely and shifted to non-GLP-1 peptides like BPC-157, MK-677, Semax, and Hexarelin, which carry their own regulatory questions but less FTC attention so far.
The cost structure is shifting. A compounded semaglutide vial that sold for $199 a month in 2023 now often lists at $299 with a separate $49 consult fee. The FTC letters did not cause that increase directly. But compliance costs, legal review, and reduced ad reach all feed into pricing.
What practitioners are watching: enforcement patterns and gray areas
Practitioners who prescribe compounded GLP-1s are watching three things. First, whether the FTC moves from warning letters to formal complaints. Warning letters carry no fine. Complaints do. Second, whether state attorneys general adopt the FTC's language in their own actions. Several states have already used similar phrasing in cease-and-desist letters. Third, whether the FDA's compounding restrictions on tirzepatide create a spillover effect on semaglutide advertising even while semaglutide remains in shortage.
The FDA investigation into compounded tirzepatide after troubling findings adds another layer. A pharmacy that receives an FDA Form 483 for subpotent product may also face FTC scrutiny if its ads claimed consistent potency. The two agencies share referral pathways.
One gray area is social media. FTC rules apply to influencer posts, affiliate links, and even organic-looking content if a seller compensates the creator. A TikTok video showing a compounded semaglutide vial with a discount code is an ad. The FTC letters name several sellers who used exactly that model.
Likely trajectory: what the next 12 months look like
Expect three developments. 1) The FTC will issue more warning letters, likely targeting sellers who use "research purposes only" disclaimers while marketing to consumers. That disclaimer does not shield a seller when the ad copy clearly targets weight loss. 2) The FDA will finalize its position on tirzepatide compounding after the six-peptide vote shifts compounding rules. 3) Payment processors will tighten their own policies. Several already refuse to process transactions for compounded GLP-1 sellers who use certain ad claims.
Sellers who survive this period will adopt a compliance-first ad model. That means no before-and-after photos, no celebrity endorsements, no "FDA-approved" language, and clear prescription disclosures. It also means separating research peptides like BPC-157, MK-677, Semax, and Hexarelin from GLP-1 products in all marketing. The FTC has not yet targeted those peptides in the same way, but the legal principle applies: any health claim requires substantiation.
Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.